MA32577B1 - Anticorps neutralisants le virus de l'influenza a et leurs utilisations - Google Patents
Anticorps neutralisants le virus de l'influenza a et leurs utilisationsInfo
- Publication number
- MA32577B1 MA32577B1 MA33633A MA33633A MA32577B1 MA 32577 B1 MA32577 B1 MA 32577B1 MA 33633 A MA33633 A MA 33633A MA 33633 A MA33633 A MA 33633A MA 32577 B1 MA32577 B1 MA 32577B1
- Authority
- MA
- Morocco
- Prior art keywords
- virus
- antibodies
- influenza
- neutralizing antibodies
- subtype
- Prior art date
Links
Classifications
-
- C07K16/108—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne des anticorps, et des fragments de liaison antigénique de ceux-ci, qui se lient à l'hémagglutinine et neutralisent un sous-type du groupe 1 et un sous-type du groupe 2 du virus influenza a. La description concerne également des acides nucléiques qui codent pour, des cellules b immortalisées et des cellules plasmatiques uniques cultivées qui produisent, et des épitopes qui se lient à, ces anticorps et fragments d'anticorps. L'invention concerne en outre l'utilisation des anticorps, des fragments d'anticorps, et des épitopes dans des procédés de dépistage ainsi que dans le diagnostic, le traitement et la prévention d'une infection par le virus influenza a.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8383808P | 2008-07-25 | 2008-07-25 | |
| US18158209P | 2009-05-27 | 2009-05-27 | |
| PCT/IB2009/006616 WO2010010466A2 (fr) | 2008-07-25 | 2009-07-27 | Anticorps neutralisant anti-virus influenza a et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32577B1 true MA32577B1 (fr) | 2011-08-01 |
Family
ID=41570664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33633A MA32577B1 (fr) | 2008-07-25 | 2011-02-22 | Anticorps neutralisants le virus de l'influenza a et leurs utilisations |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8685402B2 (fr) |
| EP (2) | EP2313433A2 (fr) |
| JP (3) | JP5607620B2 (fr) |
| KR (2) | KR101732056B1 (fr) |
| CN (2) | CN102164613B (fr) |
| AU (2) | AU2009275227A1 (fr) |
| BR (1) | BRPI0911699B8 (fr) |
| CA (2) | CA2731686C (fr) |
| CO (1) | CO6341572A2 (fr) |
| CR (2) | CR20110079A (fr) |
| EC (1) | ECSP11010823A (fr) |
| ES (1) | ES2662519T3 (fr) |
| GT (1) | GT201100023A (fr) |
| IL (2) | IL210771A0 (fr) |
| MA (1) | MA32577B1 (fr) |
| MX (2) | MX2011000768A (fr) |
| NZ (2) | NZ590890A (fr) |
| RU (1) | RU2553325C2 (fr) |
| WO (2) | WO2010010466A2 (fr) |
| ZA (2) | ZA201101113B (fr) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2708221C (fr) | 2007-12-06 | 2017-07-25 | Wayne A. Marasco | Anticorps contre le virus de la grippe et procedes pour leur utilisation |
| MX2011000768A (es) * | 2008-07-25 | 2011-10-05 | Inst Research In Biomedicine | Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos. |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| EA021977B1 (ru) * | 2010-03-08 | 2015-10-30 | Селлтрион, Инк. | Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а |
| ES2687706T3 (es) * | 2010-06-17 | 2018-10-26 | Trellis Bioscience, Llc | Anticuerpos útiles en la inmunización pasiva contra la gripe |
| US9534042B2 (en) * | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
| WO2012045001A2 (fr) * | 2010-09-30 | 2012-04-05 | Vanderbilt University | Anticorps dirigés contre le virus de la grippe, immunogènes et leurs utilisations |
| EP2699688A1 (fr) | 2011-04-20 | 2014-02-26 | The Trustees Of The University Of Pennsylvania | Régimes et compositions pour l'immunisation passive médiée par aav contre des agents pathogènes en suspension dans l'air |
| WO2013007770A1 (fr) * | 2011-07-14 | 2013-01-17 | Crucell Holland B.V. | Molécules de liaison humaines pouvant neutraliser les virus de la grippe a des groupes phylogénétiques 1 et 2 et les virus de la grippe b |
| SI3418300T1 (sl) * | 2011-07-18 | 2021-03-31 | Institute For Research In Biomedicine | Nevtralizirajoča protitelesa proti virusu influence A in njihove uporabe |
| CN107417789A (zh) * | 2011-07-18 | 2017-12-01 | 生物医学学会 | 中和抗甲型流感病毒抗体及其用途 |
| AU2012289926A1 (en) * | 2011-08-03 | 2014-03-13 | Children's Medical Center Corporation | A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin |
| EP2748184A1 (fr) * | 2011-08-27 | 2014-07-02 | Universität Zürich | Anticorps réactifs à souches multiples pour la thérapie et le diagnostic de la grippe |
| ES2641257T3 (es) | 2011-09-30 | 2017-11-08 | Celltrion, Inc. | Molécula de unión que tiene actividad neutralizadora contra el virus de la influenza A producida a partir de células B humanas |
| WO2013059524A2 (fr) * | 2011-10-18 | 2013-04-25 | Emory University | Anticorps antigrippaux |
| KR20130059721A (ko) * | 2011-11-29 | 2013-06-07 | (주)셀트리온 | 인간 b 세포에서 생산된 인플루엔자 a 바이러스 중화 활성을 가지는 결합 분자 |
| CA2892992A1 (fr) | 2011-12-02 | 2013-06-06 | Aimm Therapeutics B.V. | Anticorps specifiques au virus de la grippe a |
| US10654915B2 (en) * | 2011-12-05 | 2020-05-19 | Trellis Bioscience, Llc | Antibodies useful in passive influenza immunization |
| WO2013088367A1 (fr) * | 2011-12-12 | 2013-06-20 | Novartis Ag | Analyse pour hémagglutinines du virus de la grippe |
| KR101749316B1 (ko) | 2011-12-15 | 2017-06-21 | (주) 에이프로젠 | H1n1―감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물 |
| RU2502745C2 (ru) * | 2011-12-30 | 2013-12-27 | Общество с ограниченной ответственностью "Технофарма" | Наноантитело "anti-flu", рекомбинантные вирусные векторы и фармацевтические композиции для профилактики и терапии гриппа типа а |
| EP2822968B1 (fr) * | 2012-03-08 | 2018-01-10 | Janssen Vaccines & Prevention B.V. | Molécules de liaison humaine capables de se lier à et de neutraliser des virus de la grippe b et leurs utilisations |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| MX378749B (es) * | 2012-05-10 | 2025-03-10 | Massachussetts Institute Of Tech | Agentes para neutralizacion de influenza. |
| CN103665157B (zh) * | 2012-09-14 | 2016-06-29 | 中国科学院上海生命科学研究院 | 一种抗流感病毒广谱中和性的中和分子1c4 |
| CN103665154B (zh) * | 2012-09-14 | 2016-08-03 | 中国科学院上海生命科学研究院 | 一种抗流感病毒广谱中和性的中和分子3c4 |
| CN103665155B (zh) * | 2012-09-14 | 2016-07-06 | 中国科学院上海生命科学研究院 | 一种抗流感病毒广谱中和性的中和分子1f2 |
| CN103665156B (zh) * | 2012-09-14 | 2016-08-03 | 中国科学院上海生命科学研究院 | 一种抗流感病毒广谱中和性的结合分子3e1 |
| MA38176A1 (fr) * | 2012-11-13 | 2017-06-30 | Genentech Inc | Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a |
| MX387277B (es) | 2013-03-14 | 2025-03-12 | Contrafect Corp | Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada. |
| KR20140118682A (ko) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 a 바이러스 중화 결합 분자를 포함하는 조성물 |
| WO2014161483A1 (fr) * | 2013-04-02 | 2014-10-09 | 厦门大学 | Anticorps monoclonal à spectre large identifiant le domaine structurel ha1 des protéines d'hémagglutinine de virus de la grippe |
| AU2014329609B2 (en) | 2013-10-02 | 2019-09-12 | Humabs Biomed Sa | Neutralizing anti-influenza A antibodies and uses thereof |
| WO2015068781A1 (fr) * | 2013-11-06 | 2015-05-14 | 国立大学法人大阪大学 | Anticorps présentant une large activité neutralisante contre le virus de la grippe a de groupe 1 |
| US10639370B2 (en) | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| JP6712428B2 (ja) | 2014-02-04 | 2020-06-24 | コントラフェクト コーポレイション | インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法 |
| CN104892753B (zh) * | 2014-03-07 | 2019-11-29 | 神州细胞工程有限公司 | 一种中和人感染h7n9甲型流感病毒的抗体及其用途 |
| UA123986C2 (uk) | 2014-05-13 | 2021-07-07 | Дзе Трастіз Оф Дзе Юніверсіті Оф Пенсильванія | Композиція, яка містить aav, який експресує конструкцію антитіл з подвійною специфічністю, і її застосування |
| CA2954518C (fr) * | 2014-07-14 | 2024-02-20 | The Penn State Research Foundation | Compositions et procedes de ciblage du recepteur de proteine tensioactive a |
| CN119161468A (zh) | 2014-07-15 | 2024-12-20 | 免疫医疗有限责任公司 | 中和抗乙型流感抗体及其用途 |
| WO2016010160A1 (fr) * | 2014-07-18 | 2016-01-21 | 国立感染症研究所長が代表する日本国 | Anticorps anti-virus de la grippe et son utilisation |
| US20180008702A1 (en) | 2014-12-05 | 2018-01-11 | Celltrion Inc. | Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same |
| WO2016089181A1 (fr) * | 2014-12-05 | 2016-06-09 | (주)셀트리온 | Composition d'adjuvant contenant au moins une molécule liant au virus de la grippe et neutralisant ce dernier et composition vaccinale contenant cette molécule |
| TWI701258B (zh) | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| US11535665B2 (en) | 2015-05-13 | 2022-12-27 | The Trustees Of The University Of Pennsylvania | AAV-mediated expression of anti-influenza antibodies and methods of use thereof |
| BR112017025496A2 (pt) | 2015-06-01 | 2018-08-07 | Medimmune, Llc | Moléculas de ligação neutralizantes anti- influenza e usos das mesmas |
| US10513553B2 (en) | 2015-11-13 | 2019-12-24 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| CN116271017A (zh) | 2016-01-13 | 2023-06-23 | 免疫医疗有限责任公司 | 治疗甲型流感的方法 |
| EP3419663A1 (fr) | 2016-02-24 | 2019-01-02 | Visterra, Inc. | Formulations de molécules d'anticorps contre le virus de la grippe |
| KR102037041B1 (ko) * | 2016-08-10 | 2019-10-29 | (주)셀트리온 | 항-인플루엔자 바이러스 항체의 안정한 액체 약제학적 제제 |
| JP2017086068A (ja) * | 2016-10-31 | 2017-05-25 | インスティテュート・フォー・リサーチ・イン・バイオメディシンInstitute For Research In Biomedicine | A型インフルエンザウイルス中和抗体及びその使用法 |
| RU2664184C2 (ru) * | 2016-12-30 | 2018-08-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA1FI6-Intht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IgA1 |
| RU2656142C1 (ru) * | 2016-12-30 | 2018-05-31 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA1FI6-ht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IGA1 |
| RU2671477C2 (ru) * | 2016-12-30 | 2018-10-31 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA2m1F16-ht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IGA2m1 |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| US10786568B2 (en) | 2017-02-28 | 2020-09-29 | The Trustees Of The University Of Pennsylvania | AAV mediated influenza vaccines |
| SMT202400080T1 (it) | 2017-02-28 | 2024-05-14 | Univ Pennsylvania | Vettore di clade f di virus adenoassociato (aav) e relativi usi |
| JP7403733B2 (ja) | 2017-09-04 | 2023-12-25 | 国立感染症研究所長 | インフルエンザhaスプリットワクチンの製造方法 |
| EP3684927B1 (fr) | 2017-09-18 | 2024-05-29 | Amyris, Inc. | Procédés d'intégration génomique pour des cellules hôtes de kluyveromyces |
| CN111433369A (zh) * | 2017-09-18 | 2020-07-17 | 阿迈瑞斯公司 | 用于毕赤酵母和其他宿主细胞基因组整合的方法 |
| CN109988236B (zh) * | 2017-12-30 | 2022-04-01 | 中国科学院天津工业生物技术研究所 | 一种流感病毒抗体的应用 |
| PE20210651A1 (es) * | 2018-01-23 | 2021-03-26 | Janssen Vaccines And Prevention B V | Vacunas contra virus de la gripe y usos de las mismas |
| JP6622825B2 (ja) * | 2018-01-25 | 2019-12-18 | インスティテュート・フォー・リサーチ・イン・バイオメディシンInstitute For Research In Biomedicine | A型インフルエンザウイルス中和抗体及びその使用法 |
| JP7372925B2 (ja) | 2018-01-26 | 2023-11-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | インフルエンザヘマグルチニンに対するヒト抗体 |
| PH12021550175A1 (en) | 2018-07-23 | 2022-07-11 | Japan As Represented By Director General Of Nat Institute Of Infectious Diseases | Composition containing influenza vaccine |
| KR20210134321A (ko) * | 2019-02-01 | 2021-11-09 | 노바록 바이오테라퓨틱스 리미티드 | 항-클라우딘 18 항체 및 이의 이용 방법 |
| BR112021017310A8 (pt) | 2019-03-04 | 2022-12-06 | Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases | Método para produzir vacina fracionada de ha de influenza |
| WO2020198329A1 (fr) | 2019-03-25 | 2020-10-01 | Visterra, Inc. | Compositions et méthodes pour traiter et prévenir la grippe |
| JP2020048568A (ja) * | 2019-11-22 | 2020-04-02 | インスティテュート・フォー・リサーチ・イン・バイオメディシンInstitute For Research In Biomedicine | A型インフルエンザウイルス中和抗体及びその使用法 |
| CN115551885A (zh) | 2019-12-11 | 2022-12-30 | 威特拉公司 | 用于治疗和预防流感的组合物和方法 |
| WO2021201677A1 (fr) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions et procédés ciblant la grippe |
| CN111825763B (zh) * | 2020-07-15 | 2022-04-19 | 扬州大学 | 流感病毒ha蛋白茎部特异性单克隆抗体及其制备方法和应用 |
| CN114181303B (zh) * | 2020-09-14 | 2022-12-23 | 东莞市朋志生物科技有限公司 | 抗甲型流感病毒的抗体和试剂盒 |
| CN116670152A (zh) | 2020-12-01 | 2023-08-29 | 宾夕法尼亚州大学信托人 | 具有组织特异性靶向基序的新型组合物和含有其的组合物 |
| JP2024515788A (ja) | 2021-04-27 | 2024-04-10 | ジェネレーション バイオ カンパニー | 治療抗体を発現する非ウイルスdnaベクター及びその使用 |
| CA3245737A1 (fr) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Compositions vaccinales prime-boost hétérologues et méthodes d’utilisation |
| KR20240088574A (ko) | 2022-11-21 | 2024-06-20 | (주)샤페론 | 인플루엔자 바이러스에 대한 단일 도메인 항체 및 이의 용도 |
| CN119930806B (zh) * | 2025-01-21 | 2025-12-02 | 中国医学科学院病原生物学研究所 | 一种甲型流感病毒中和抗体及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US630064A (en) * | 1899-02-10 | 1899-08-01 | William Martindale | Safety-hook. |
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) * | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) * | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) * | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| RU2031941C1 (ru) * | 1991-03-14 | 1995-03-27 | Научно-исследовательский институт гриппа РАМН | Штамм вируса гриппа а(нini) для получения живой гриппозной интраназальной вакцины для взрослых и детей |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| DK1143006T3 (da) | 1995-08-18 | 2008-07-14 | Morphosys Ip Gmbh | Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker |
| AU8063798A (en) * | 1997-06-19 | 1999-01-04 | Regents Of The University Of California, The | Secretory immunoglobulin produced by single cells and methods for making and using same |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| WO2001062907A1 (fr) * | 2000-02-22 | 2001-08-30 | Medical & Biological Laboratories Co., Ltd. | Bibliotheque d'anticorps |
| WO2004007667A2 (fr) | 2002-07-11 | 2004-01-22 | The General Hospital Corporation | Polynucleotide et polypeptide de regulation du metabolisme des graisses et leurs utilisations |
| CN1756562A (zh) * | 2003-03-07 | 2006-04-05 | 麦克公司 | 流感病毒疫苗 |
| CN1867355A (zh) | 2003-08-11 | 2006-11-22 | 财团法人阪大微生物病研究会 | 包含诱导粘膜免疫的佐剂的新型疫苗 |
| WO2006124269A2 (fr) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Anticorps monoclonaux humains se fixant a l'antigene-1 tres tardif pour le traitement de l'inflammation ainsi que d'autres troubles |
| MY144906A (en) | 2005-10-21 | 2011-11-30 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
| EP2522678A1 (fr) * | 2006-05-15 | 2012-11-14 | Sea Lane Biotechnologies, LLC | Anticorps neutralisants des virus de la grippe |
| EA017203B1 (ru) * | 2006-09-07 | 2012-10-30 | Круселл Холланд Б.В. | Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение |
| NZ576040A (en) | 2006-10-02 | 2011-06-30 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
| CA2668800A1 (fr) | 2006-11-08 | 2008-06-05 | Macrogenics West, Inc. | Tes7, et anticorps se liant a celui-ci |
| EP1925318A1 (fr) * | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Vaccin à base de virus modifié de vaccin Ankara (MVA) recombinant contre la grippe aviaire |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| JP5346820B2 (ja) | 2007-03-13 | 2013-11-20 | エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー | H5n1亜型a型インフルエンザウィルスに対する抗体 |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| MX2011000768A (es) * | 2008-07-25 | 2011-10-05 | Inst Research In Biomedicine | Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos. |
| US8871207B2 (en) * | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
-
2009
- 2009-07-27 MX MX2011000768A patent/MX2011000768A/es not_active Application Discontinuation
- 2009-07-27 NZ NZ590890A patent/NZ590890A/xx not_active IP Right Cessation
- 2009-07-27 JP JP2011519252A patent/JP5607620B2/ja active Active
- 2009-07-27 CN CN200980132989.9A patent/CN102164613B/zh active Active
- 2009-07-27 AU AU2009275227A patent/AU2009275227A1/en not_active Abandoned
- 2009-07-27 NZ NZ590891A patent/NZ590891A/xx not_active IP Right Cessation
- 2009-07-27 BR BRPI0911699A patent/BRPI0911699B8/pt active IP Right Grant
- 2009-07-27 WO PCT/IB2009/006616 patent/WO2010010466A2/fr not_active Ceased
- 2009-07-27 US US12/509,835 patent/US8685402B2/en active Active
- 2009-07-27 EP EP09759983A patent/EP2313433A2/fr not_active Withdrawn
- 2009-07-27 CA CA2731686A patent/CA2731686C/fr active Active
- 2009-07-27 KR KR1020117003526A patent/KR101732056B1/ko active Active
- 2009-07-27 RU RU2011105062/10A patent/RU2553325C2/ru active
- 2009-07-27 CA CA2733218A patent/CA2733218A1/fr not_active Abandoned
- 2009-07-27 CN CN2009801329884A patent/CN102216327A/zh active Pending
- 2009-07-27 KR KR1020117003495A patent/KR20110049802A/ko not_active Withdrawn
- 2009-07-27 WO PCT/IB2009/006623 patent/WO2010010467A2/fr not_active Ceased
- 2009-07-27 JP JP2011519253A patent/JP2011528902A/ja active Pending
- 2009-07-27 AU AU2009275226A patent/AU2009275226B2/en active Active
- 2009-07-27 US US12/509,731 patent/US9340603B2/en active Active
- 2009-07-27 MX MX2011000767A patent/MX2011000767A/es active IP Right Grant
- 2009-07-27 ES ES09745097.7T patent/ES2662519T3/es active Active
- 2009-07-27 EP EP09745097.7A patent/EP2313112B1/fr active Active
-
2011
- 2011-01-20 IL IL210771A patent/IL210771A0/en unknown
- 2011-01-20 IL IL210772A patent/IL210772A0/en unknown
- 2011-01-21 GT GT201100023A patent/GT201100023A/es unknown
- 2011-02-09 CO CO11015221A patent/CO6341572A2/es active IP Right Grant
- 2011-02-11 EC EC2011010823A patent/ECSP11010823A/es unknown
- 2011-02-11 ZA ZA2011/01113A patent/ZA201101113B/en unknown
- 2011-02-11 CR CR20110079A patent/CR20110079A/es unknown
- 2011-02-14 CR CR20110084A patent/CR20110084A/es unknown
- 2011-02-14 ZA ZA2011/01150A patent/ZA201101150B/en unknown
- 2011-02-22 MA MA33633A patent/MA32577B1/fr unknown
-
2014
- 2014-08-28 JP JP2014174221A patent/JP6022515B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA32577B1 (fr) | Anticorps neutralisants le virus de l'influenza a et leurs utilisations | |
| MA32561B1 (fr) | Anticorps neutralisant le cytomegalovirus humain et leurs utilisations | |
| MA49599A1 (fr) | Anticorps spécifiques à cd47 et pd-l1 | |
| MA35740B1 (fr) | Compositions et procédés pour des anticorps ciblant le facteur p | |
| MA32566B1 (fr) | Anticorps neutralisant les cytomégalovirus humains et leurs utilisations | |
| EA200800812A1 (ru) | Композиции антитела против cd3 | |
| MA35174B1 (fr) | Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines | |
| MA30497B1 (fr) | Anticorps et immunco-conjugues, et leurs utilisations. | |
| MA40662A1 (fr) | Anticorps contre tigit | |
| MX352338B (es) | Anticuerpos neutralizantes del virus de la influenza a y usos de estos. | |
| MA46619B1 (fr) | Anticorps anti-il-33 et leurs utilisations | |
| NZ592054A (en) | Dengue virus neutralizing antibodies and uses thereof | |
| MA40041A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| MA33276B1 (fr) | Anticorps spécifiques à la cadhérine-17 | |
| BR112014031689A2 (pt) | anticorpos reativos cruzados anti-jagged 1/jagged 2, anticorpos anti-jagged ativáveis e métodos de uso deles | |
| MA42530B1 (fr) | Constructions d'anticorps bispécifiques se liant à dll3 et à cd3 | |
| WO2007089753A3 (fr) | Anticorps monoclonaux qui se lient à l'hémagglutinine de la sous-classe h5 du virus de la grippe aviaire et leurs utilisations | |
| MA34461B1 (fr) | Anticorps anti-peptide beta-amyloide n3pgiu et leurs utilisations | |
| MA39061A1 (fr) | Modulateurs d'aplnr et leurs utilisations | |
| MA34753B1 (fr) | Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes | |
| MA33402B1 (fr) | Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps | |
| MA38161A1 (fr) | Anticorps anti-bmp-6 | |
| EA201390874A1 (ru) | Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение | |
| WO2011092593A3 (fr) | Anticorps neutralisant le vih-1 et leurs utilisations | |
| WO2011035205A3 (fr) | Anticorps dirigés contre candida, leurs collectes et procédés d'utilisation |